As the number of patients receiving AOMs, such as GLP-1 RAs, continues to increase, recent studies have begun to explore the potential therapeutic effects of GLP-1 RAs on psychological behavior and olfactory networks, building upon earlier findings linking obesity and olfaction [13]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.